The radiohybrid (rh) concept to design targeted (and
chemically
identical) radiotracers for imaging or radionuclide therapy of tumors
has gained momentum. For this strategy, a new bifunctional Silicon-based
Fluoride Acceptor (SiFA) moiety (SiFA)SeFe was synthesized,
endowed with improved hydrophilicity and high versatility of integration
into rh-compounds. Preliminary radiolabeling and stability studies
under different conditions were conducted using model bioconjugate
peptides. Further, three somatostatin receptor 2 (sstR2)-targeted
rh-compounds ((SiFA)SeFe-rhTATE1–3, TATE = (Tyr3)-octreotate) were developed. Compound (SiFA)SeFe-rhTATE3, enables labeling with 18F for PET imaging or chelation
of 177Lu for therapy. The rh-compounds possess comparable
receptor binding affinity and in vitro performance
as good as the clinically proven gold standards. SstR2-specificity
was further shown for (SiFA)SeFe-rhTATE2 using the chicken
chorioallantoic membrane (CAM) model. The biodistribution of two compounds
in mice showed high accumulation in tumors and excretion via the kidneys,
demonstrating the clinical applicability of the (SiFA)SeFe moiety.